Journal of Psychopharmacology · 2013 · 101 citations · 27 references
MedicinePharmacologyPsychiatryNeuropharmacologyPsychopharmacologySubstance Use DisordersAddictionDrug DependenceDrugs Of AbusePharmacoepidemiologySubstance IntoxicationSubstance UseDrug Use DisorderDrug Use EpidemiologyDrug User HealthPsychedelic Drug UseSerotonergic System EffectsSide Effect Profile
This paper presents original research on prevalence, user characteristics and effect profile of N,N-dimethyltryptamine (DMT), a potent hallucinogenic which acts primarily through the serotonergic system. Data were obtained from the Global Drug Survey (an anonymous online survey of people, many of whom have used drugs) conducted between November and December 2012 with 22,289 responses. Lifetime prevalence of DMT use was 8.9% (n=1980) and past year prevalence use was 5.0% (n=1123). We explored the effect profile of DMT in 472 participants who identified DMT as the last new drug they had tried for the first time and compared it with ratings provided by other respondents on psilocybin (magic mushrooms), LSD and ketamine. DMT was most often smoked and offered a strong, intense, short-lived psychedelic high with relatively few negative effects or "come down". It had a larger proportion of new users compared with the other substances (24%), suggesting its popularity may increase. Overall, DMT seems to have a very desirable effect profile indicating a high abuse liability that maybe offset by a low urge to use more.
27
Identification of a serotonin/glutamate receptor complex implicated in psychosis
Javier González‐Maeso, Rosalind L. Ang, Tony Yuen et al. · Nature · 2008 · 780 citations · Full text
Medicine, Neuroscience, Psychiatry +12
Mephedrone, new kid for the chop?
Adam Winstock, Luke Mitcheson, Paolo Deluca et al. · Addiction · 2010 · 357 citations
Dose-Response Study of N,N-Dimethyltryptamine in Humans
Rick J. Strassman · Archives of General Psychiatry · 1994 · 284 citations